

Financial news for THRX dated on 2016-01-08: Theravance Reports Name Change to Innoviva, Ticker changing to INVA

Financial news for THRX dated on 2015-12-02: UPDATE: Theravance Reports Prelim. Tender Offer Results: ~2.58M Shares of Common Stock at \$9.25/Share for Aggregate Cost of ~\$23.9M

Financial news for THRX dated on 2015-12-02: Theravance Inc Reports Prelim Tender Offer Results

Financial news for THRX dated on 2015-10-30: Theravance Reports Commencement of Self-Tender Offer for Up to \$75M in Common Shares

Financial news for THRX dated on 2015-10-28: Theravance Resumes Trading +4%

Financial news for THRX dated on 2015-10-28: Shares of Theravance Are Currently Halted; Just Released Earnings

Financial news for THRX dated on 2015-10-28: Theravance Reports \$150M Buyback

Financial news for THRX dated on 2015-10-28: Theravance Reports Q3 EPS \$(0.04) vs. Est. \$(0.03), Rev. \$13.562M vs. Est. \$15.23M

Financial news for THRX dated on 2015-09-24: Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan

Financial news for THRX dated on 2015-09-09: Theravance Just Lost Its Catalyst

Financial news for THRX dated on 2015-09-08: Biotech Hit After-Hours

Financial news for THRX dated on 2015-09-08: Theravance Resumes Trading, Halted LULD At \$11.45, Opens \$12.75

Financial news for THRX dated on 2015-09-08: Theravance Shares Halted Down 20%, LULD Circuit Breaker

Financial news for THRX dated on 2015-09-08: Theravance Resumes Traing, Halted At \$15.95, Open Resumption Print \$11.45

Financial news for THRX dated on 2015-09-08: GSK Shares Fall Following Announcement of No Statistically Significance SUMMIT COPD CV Survival Study Results

Financial news for THRX dated on 2015-09-08: Theravance To Resume Trading At 3:10pm ET

Financial news for THRX dated on 2015-09-08: UPDATE: GSK, Theravance Report Results From the SUMMIT COPD CV Survival Study; Primary Endpoint Not Statistically Significant

Financial news for THRX dated on 2015-09-08: GSK, Theravance Report Results From the SUMMIT COPD CV Survival Study; Primary Endpoint Not Statistically Significant

Financial news for THRX dated on 2015-09-08: Theravance Halted News Pending

Financial news for THRX dated on 2015-07-29: Theravance Reports Q2 EPS \$(0.07) vs. Est. \$(0.06)

Financial news for THRX dated on 2015-07-13: Theravance, Inc. Appoints Michael Faerm as Chief Business Officer

Financial news for THRX dated on 2015-07-13: Short-Sellers Betting Against These Biotechs

Financial news for THRX dated on 2015-05-11: GlaxoSmithKline Buys 85,579 Shares Of Theravance @\$16.00/Share -Form 4

Financial news for THRX dated on 2015-05-07: Theravance Reports Q1 Sales \$20.4M vs \$14.87M Est., GAAP Loss of \$1.29/Share May Not Compare Loss of \$0.04/Share Est.

Financial news for THRX dated on 2015-05-06: Theravance Reports Q1 Loss of \$0.09/Share vs Loss of \$0.08/Share Est.

Financial news for THRX dated on 2015-04-30: Glaxo, Theravance Announces BREO ELIPTA Approved by FDA for Treatment of Adults with Asthma in US

Financial news for THRX dated on 2015-03-20: Morning Market Losers

Financial news for THRX dated on 2015-03-20: 8-K from Theravance Shows Co., Glaxo Introducing REVLAR ELLIPTA in Italy

Financial news for THRX dated on 2015-03-19: Shares of Theravance to Resume Trade at 6:20 p.m. EDT

Financial news for THRX dated on 2015-03-19: Glaxo, Theravance Announce FDA Panel Voted to Support Efficacy, Safety, Voted Against Approval for Proposed Indication in 12-17 Olds

Financial news for THRX dated on 2015-03-19: Hearing FDA Panel Has Said Glaxo, Theravance's BREO ELLIPTA In Need of Larger Safety Trial for Both Adults, Children

Financial news for THRX dated on 2015-03-19: FDA Panel Has Voted Glaxo, Theravance's BREO ELLIPTA Failed to Win Backing for Asthma Treatment

Financial news for THRX dated on 2015-03-19: Theravance Release Alerts of Halt in Trading of Common Stock; Says FDA Joint Advisory Committee to Review Supplemental NDA for BREO ELLIPTA for Asthma

Financial news for THRX dated on 2015-03-19: Theravance Halted, News Pending

Financial news for THRX dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for THRX dated on 2015-02-18: Theravance Reports Inline Q4 EPS Loss \$0.14 Vs Est \$0.65, Sales \$7.28M Vs Est \$5.42M

Financial news for THRX dated on 2015-02-10: Theravance Reports Initiation of Patient Registry Study for VIBATIV(R)

Financial news for THRX dated on 2015-02-06: UPDATE: Theravance Date for FDA Panel Review of NDA Set for Mar. 19, 2015

Financial news for THRX dated on 2015-02-06: Theravance Reports FDA Advisory Committee to Review BREO ELLIPTA (FF/VI) For Asthma

Financial news for THRX dated on 2014-11-04: GlaxoSmithKline Buys 832,456 Shares of Theravance @ \$15.36/Share -Form 4

Financial news for THRX dated on 2014-10-30: Theravance, Inc. Reports Q3 EPS of \$(0.19) vs \$(0.14) Est

Financial news for THRX dated on 2014-10-20: Bank Of America Q3 Small & Mid-Cap Biotech Preview

Financial news for THRX dated on 2014-10-17: Theravance Announces Data Published on Anoro Ellipta Demonstrate Improved Lung Function vs Tiotropium

Financial news for THRX dated on 2014-10-09: Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President And CFO

Financial news for THRX dated on 2014-09-04: Theravance, Glaxosmithkline Announce Japan Launch Of Anoro Ellipta, Theravance to Make \$10M Milestone Payment to GSK Following Launch

Financial news for THRX dated on 2014-08-14: 13F from Baupost Group Shows New Stakes in eBay, Boyd Gaming, Raised Stakes in Citi, Keryx, Triquant Semi, RF Micro, Lowered Stakes in Theravance

Financial news for THRX dated on 2014-08-06: Theravance Reports Q2 Loss from Cont. Ops. \$0.18/Share

Financial news for THRX dated on 2014-08-06: Theravance Announces Michael Aguiar President and CEO, Is also CFO

Financial news for THRX dated on 2014-07-27: Barron's Recap: Ready To Wear?

Financial news for THRX dated on 2014-07-24: UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue

Financial news for THRX dated on 2014-07-24: Bank of America Downgrades Theravance, Inc. to Neutral, Lowers PT to \$31.00

Financial news for THRX dated on 2014-07-21: UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends Weigh On Value

Financial news for THRX dated on 2014-07-07: Japan Allows Anoro Ellipta For the Treatment of COPD

Financial news for THRX dated on 2014-07-02: Theravance, Inc. Appoints Theodore J.

Witek, Jr. As Senior VP, Corporate Partnerships, Clinical And Medical Affairs

Financial news for THRX dated on 2014-06-30: GSK, Theravance Announce Submission to US Regulatory Authorities for Fluticasone Furoate/Vilanterol in Asthma

Financial news for THRX dated on 2014-06-12: Theravance Has Named George Abercrombie as Senior VP, Corporate Partnerships, Commercial

Financial news for THRX dated on 2014-06-12: UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion

Financial news for THRX dated on 2014-06-12: Benzinga's Top Downgrades

Financial news for THRX dated on 2014-06-12: Stifel Nicolaus Downgrades Theravance, Inc. to Hold, Removes \$37.86 PT

Financial news for THRX dated on 2014-06-11: UPDATE: Glaxo, Theravance Report Positive Data from Two Studies Considering Efficacy, Safety of Incruse(TM) Ellipta(R) Plus Relvar(R)/Breo(R) Ellipta(R) for COPD

Financial news for THRX dated on 2014-06-11: Glaxo, Theravance Report Positive Data from Two Studies Considering Efficacy, Safety of Incruse(TM) Ellipta(R) Plus Relvar(R)/Breo(R) Ellipta(R) for COPD

Financial news for THRX dated on 2014-06-03: Mid-Day Market Movers For Tuesday, June 3, 2014

Financial news for THRX dated on 2014-06-03: Morning Market Losers

Financial news for THRX dated on 2014-06-02: Baird Downgrades Theravance, Inc. to Neutral, Lowers PT to \$21.00

Financial news for THRX dated on 2014-05-15: Theravance Announces Effectiveness of Form 10 Registration Statement of Theravance Biopharma; Expects to Complete Distribution and Separation on June 2

Financial news for THRX dated on 2014-05-15: UPDATE: Morgan Stanley Reiterates On Theravance Following Anoro Launch

Financial news for THRX dated on 2014-05-13: Theravance Shareholder Glaxosmithkline Buys 317,770 Shares @\$26.89/Share -Form 4

Financial news for THRX dated on 2014-05-08: 8-K from Theravance Shows Rick Winningham Will Lead Theravance Bio for Up to Nine Months, Will Remain Pres, CEO of Theravance

Financial news for THRX dated on 2014-05-08: Glaxo Receives EU Marketing Authorization for Anoro, Says Theravance Obligated to Make Milestone Payment of \$15M

Financial news for THRX dated on 2014-05-05: Form 8-K from Theravance Shows Co. Sets May 15th as Spinoff of Record Date

Financial news for THRX dated on 2014-05-01: Theravance to Present New Data Confirming in vitro Potency of VIBATIV and Efficacy in Patients with Complicated Skin and Skin Structure Infections Including MRSA at 2014 ECCMID Conference

Financial news for THRX dated on 2014-04-30: Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia

Financial news for THRX dated on 2014-04-22: Form 8-K from Glaxo, Theravance Shows TGA Approval Breo Ellipta in Australia

Financial news for THRX dated on 2014-04-10: Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational LAMA for the Treatment of COPD

Financial news for THRX dated on 2014-04-10: Theravance Initiates Phase 2B Study of TD-4208

Financial news for THRX dated on 2014-04-01: Theravance Names Kevin Kwok as Head of Talent Acquisition, Strategy

Financial news for THRX dated on 2014-03-18: Theravance Reports EC Has Lifted Europe-Wide Suspension of Marketing Authorization, Amended Marketing Authorization for Vibativ

Financial news for THRX dated on 2014-03-03: Theravance Issues Update on Planned Separation of Late-Stage Partnered Respiratory Assets from Biopharma Operations, Sees Closing in Q2 Compared to Early 2014 Previously

Financial news for THRX dated on 2014-02-20: Market Wrap For February 20: S&P 500 Inches Closer To New Highs

Financial news for THRX dated on 2014-02-20: Glaxo, Theravance's ANORO Gets Positive Opinion from the CHMP in Europe

Financial news for THRX dated on 2014-02-10: Form 8-K from Theravance Shows GlaxoSmithKline Submitted Application to Chinese Regulators for Ellipta

Financial news for THRX dated on 2014-02-07: Morgan Stanley Expects Theravance to Continue to Underperform Following 4Q Earnings

Financial news for THRX dated on 2014-02-06: Theravance, Inc. Reports Q4 EPS of \$(0.46) vs \$(0.38) Est; Revenue of \$1.60M vs \$6.03M Est

Financial news for THRX dated on 2014-01-16: Theravance Exec at JPM Healthcare Conf. Says Q1 is a Likely Target for Separation of Businesses

Financial news for THRX dated on 2014-01-16: From JP Morgan Healthcare Conf.: Theravance Expecting Q1 US Release of Anoro Ellipta

Financial news for THRX dated on 2013-12-18: Glaxo Confirms ANORO ELLIPTA Approved for First Once-Daily Dual Bronchodilator for Treatment of COPD in US

Financial news for THRX dated on 2013-12-18: Glaxo, Theravance's Anoro Ellipta Approved by FDA

Financial news for THRX dated on 2013-12-16: Form 8-K from Theravance Shows Co. Reporting Positive Results from Umeclidinium Study, Cites Glaxo Group Phase 2B Efficacy, Safety Study

Financial news for THRX dated on 2013-12-06: Glaxo, Theravance Announce Results of PIVOTAL Phase III Study for Fluticasone Furoate/Vilanterol in Asthma, Says Met Primary Efficacy Endpoint

Financial news for THRX dated on 2013-12-02: Theravance Spikes to Low

Financial news for THRX dated on 2013-11-18: UPDATE: Glaxo Confirms Relvar Ellipta Wins European Marketing Authorization

Financial news for THRX dated on 2013-11-18: Glaxo Says Theravance Obligated to Make Payment of \$15M to Follow Relvar Ellipta Launch in Europe

Financial news for THRX dated on 2013-11-13: 13F Filing from Klarman's Baupost Shows Raised Stakes in Micron, Theravance, ChipMOS, Lowered Stake in BP

Financial news for THRX dated on 2013-10-24: Theravance, Inc. Reports Q3 EPS of \$(0.44) vs \$(0.79) Est

Financial news for THRX dated on 2013-09-20: US Stock Futures Signal Flat Start On Wall Street

Financial news for THRX dated on 2013-09-20: Relvar Ellipta Approved in Japan for Treatment of Asthma

Financial news for THRX dated on 2013-09-19: Shares of Theravance Open for Trade, Stock Spiking Higher, Now Up ~0.5%

Financial news for THRX dated on 2013-09-19: Shares of Theravance to Resume Trade at 2PM EDT

Financial news for THRX dated on 2013-09-19: Glaxo, Theravance Confirm Positive CHMP Opinion for Relvar Ellipta

Financial news for THRX dated on 2013-09-19: Glaxo Says Relvar Ellipta Receives CHMP Position Opinion

Financial news for THRX dated on 2013-09-19: Theravance Halted News Pending

Financial news for THRX dated on 2013-09-10: Theravance Shares Resume Trade Up ~\$1, Now at \$39.25

Financial news for THRX dated on 2013-09-10: Shares of Theravance to Resume Trade at 4:15PM EDT

Financial news for THRX dated on 2013-09-10: Glaxo, Theravance Confirms FDA Panel Has Recommended Approval for UMEC/VI 62.5/25mcg Dose for COPD

Financial news for THRX dated on 2013-09-10: FDA Panel Votes 11-2 Data Supports

Theravance, Glaxo's Anoro for Approval

Financial news for THRX dated on 2013-09-10: UPDATE: FDA Panel Voted 10-3 in Favor of Safety for Theravance, Glaxo's Anoro

Financial news for THRX dated on 2013-09-10: FDA Panel Shows Theravance, Glaxo's Anoro Demonstrated Safety

Financial news for THRX dated on 2013-09-10: UPDATE: Theravance Says Both Doses of UMEC/VI Improved Lung Function

Financial news for THRX dated on 2013-09-10: Form 8-K from MTheravance Shows Treatment with UMEC/VI 125/25 Showed Statistical Significant Improvement, Said 4 Patients Died During Study, None Related to Drug

Financial news for THRX dated on 2013-09-10: Theravance Halted with News Pending

Financial news for THRX dated on 2013-09-04: Theravance Reports Results from Phase 2B Study 0091 with TD-4208 for COPD, Says Met Primary Efficacy Endpoint

Financial news for THRX dated on 2013-08-01: Amended 13D Filing from Glaxo on Theravance Showing 26.96% Stake, Had Show 26.87% Stake as of Apr. 30th

Financial news for THRX dated on 2013-07-30: Form 8-K from Theravance Shows Co. to Sell 3.06M Unregistered Shares at \$36.50/Share to Glaxo

Financial news for THRX dated on 2013-07-25: Theravance, Inc. Reports Q2 EPS of \$(0.37) vs \$(0.46) Est; Revenue of \$1.30M, Down 9% YOY

Financial news for THRX dated on 2013-07-22: Theravance Shares Down 1.6% as Morgan Stanley Earlier Resumed Coverage with Underweight Rating, \$13 Target, Concerned with Respiratory Segment

Financial news for THRX dated on 2013-07-12: A Peek Into The Market Before The Trading Starts

Financial news for THRX dated on 2013-07-12: GlaxoSmithKline, Theravance Withdraw License Application for RELVAR ELLIPTA in Japan

Financial news for THRX dated on 2013-06-21: Theravance Reports FDA Approval of VIBATIV for Treatment of Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia, to Evaluate Commercialization Alternatives for US

Financial news for THRX dated on 2013-06-21: Market Wrap for Friday, June 21: Stocks Stabilize After Thursday's Plunge

Financial news for THRX dated on 2013-06-21: Bank of America Reiterates Buy Rating on Theravance Following Investor Meeting

Financial news for THRX dated on 2013-06-17: Bank of America Reiterates Buy Rating on Theravance Following Elan Royalty Deal Rejection

Financial news for THRX dated on 2013-06-17: Elan Says Holders Do Not Approve Theravance/Elan Royalty Participation Deal

Financial news for THRX dated on 2013-06-04: Theravance Calls for Redemption of \$172.5M in 3% Convertible Subordinated Notes

Financial news for THRX dated on 2013-05-14: Stifel Nicolaus Maintains Buy on Theravance, Inc., Raises PT to \$54.00

Financial news for THRX dated on 2013-05-13: Market Wrap for Monday, May 13: Major Averages Closed Mixed as Retail Sales Data Surpasses Expectations

Financial news for THRX dated on 2013-05-13: Mid-Afternoon Market Update: Jos. A Bank Falls as the Markets Turn Red

Financial news for THRX dated on 2013-05-13: Mid-Day Market Update: US Stocks Fall on Monday, Gold Down

Financial news for THRX dated on 2013-05-13: Mid-Morning Market Update: April Retail Sales Beat Expectations, Business Inventories for March Show a Decline

Financial news for THRX dated on 2013-05-13: Benzinga's Top Pre-Market Gainers

Financial news for THRX dated on 2013-05-13: Theravance, Elan Announce \$1B Royalty Participation Agreement

Financial news for THRX dated on 2013-05-13: Elan Comments on Royalty Participation

Agreement with Theravance

Financial news for THRX dated on 2013-05-10: UPDATE: Theravance to Make \$30M Milestone Payment to Glaxo

Financial news for THRX dated on 2013-05-10: Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

Financial news for THRX dated on 2013-05-10: Glaxo Confirming FDA Approval for Breo Ellipta

Financial news for THRX dated on 2013-05-10: Theravance Shares Spike Higher as FDA Approves Breo Ellipta

Financial news for THRX dated on 2013-04-26: Mid-Morning Market Update: Markets Open Mixed, Chevron Profit Beats Estimates

Financial news for THRX dated on 2013-04-26: Stocks Hitting 52-Week Highs

Financial news for THRX dated on 2013-04-25: Shares of Theravance Resume Trading Up ~3.8%

Financial news for THRX dated on 2013-04-25: Shares of Theravance to Resume Trading at 4:30PM EDT

Financial news for THRX dated on 2013-04-25: Theravance, Inc. Reports Q1 EPS of \$(0.39) vs \$(0.34) Est; Revenue of \$1.30M vs \$5.12M Est

Financial news for THRX dated on 2013-04-25: Theravance Announces Plan to Separate Late-Stage Partnered Respiratory Assets From Biopharmaceutical Operations

Financial news for THRX dated on 2013-04-18: Market Wrap for Thursday, April 18: Market Pullback Continues; Dow Loses 81

Financial news for THRX dated on 2013-04-18: Mid-Afternoon Market Update: Fairway Group Rises on Successful IPO as Markets Fall Further

Financial news for THRX dated on 2013-04-18: Mid-Day Market Update: Ultratech Tumbles On Downbeat Results, Theravance Rises

Financial news for THRX dated on 2013-04-18: Stocks Hitting 52-Week Highs

Financial news for THRX dated on 2013-04-18: Mid-Morning Market Update: Markets Go Red, PepsiCo Profit Beats Estimates

Financial news for THRX dated on 2013-04-18: Stifel Nicolaus Maintains Buy on Theravance, Inc., Raises PT to \$44.00

Financial news for THRX dated on 2013-04-18: Benzinga Market Primer: Thursday, April 18

Financial news for THRX dated on 2013-04-17: Glaxo Confirms FDA Panel Recommended Approval of BREO ELLIPTA for COPD

Financial news for THRX dated on 2013-04-17: Theravance Shares Resume Trading Up 13%

Financial news for THRX dated on 2013-04-17: PREVIEW: Theravance to Resume Trading at 4:25 PM ET

Financial news for THRX dated on 2013-04-17: FDA Advisory Committee Recommends Approval of BREO ELLIPTA for the Treatment of COPD

Financial news for THRX dated on 2013-04-17: FDA Panel Votes 10-3 for Safety of Glaxo, Theravance Breo

Financial news for THRX dated on 2013-04-17: FDA Panel Votes 8-5 Theravance's, Glaxo's Breo Helps Reduce Lung Disease Severity

Financial news for THRX dated on 2013-04-17: UPDATE: Glaxo, Theravance's Breo Reduces Lung Disease Exacerbations

Financial news for THRX dated on 2013-04-17: FDA Panel Votes 12-1 for Efficacy of Glaxo, Theravance's Breo

Financial news for THRX dated on 2013-04-17: Theravance Halted Ahead of FDA Advisory Committee

Financial news for THRX dated on 2013-04-17: Theravance Halted; Pending News

Financial news for THRX dated on 2013-04-15: Market Wrap for Monday, April 15: Major Sell-Off Sweeps Wall Street; Gold Plunges to 2-Year Low

Financial news for THRX dated on 2013-04-15: Benzinga's Volume Movers

Financial news for THRX dated on 2013-04-15: Theravance Shares Surge Higher as FDA Issues Staff Report on Breo Ellipta, Report Says Safety Similar to Other Drugs

Financial news for THRX dated on 2013-04-15: Morning Market Movers

Financial news for THRX dated on 2013-03-26: 13 Drugs Pending FDA Approval in 2013

Financial news for THRX dated on 2013-03-06: Theravance Announces Postponement of March 7 PDAC Meeting Due to Weather -8K

Financial news for THRX dated on 2013-03-05: Theravance FDA Panel Scheduled for March 7 has been Postponed

Financial news for THRX dated on 2013-03-05: Theravance Spokesperson Says GlaxoSmithKline is Waiting to Hear Back from FDA. Weather is a Factor on the Delay of the Posting of the Briefing Documents

Financial news for THRX dated on 2013-03-05: Theravance Release of BREO Briefing Docs for PADAC Meeting are Delayed

Financial news for THRX dated on 2013-03-05: Theravance Spikes to Lows

Financial news for THRX dated on 2013-03-04: Theravance Shares Rally as Analyst Highlights Co. as Possible Takeover Target If FDA Panel Outcome Positive

Financial news for THRX dated on 2013-03-04: Mid-Afternoon Market Update: Markets Turn Upwards, MBIA Spikes

Financial news for THRX dated on 2013-02-13: UPDATE: Stifel Nicolaus Cuts PT to \$37 on Theravance Ahead of March PADAC Meeting

Financial news for THRX dated on 2013-02-13: Stifel Nicolaus Maintains Buy on Theravance, Inc., Lowers PT to \$37.00

Financial news for THRX dated on 2013-02-12: Theravance, Inc. Reports Q4 EPS of \$(0.33) vs \$(0.36) Est; Revenue of \$5.80M vs \$3.88M Est

Financial news for THRX dated on 2013-02-11: Baird Initiates Coverage on Theravance, Inc. at Outperform, Announces \$27.00 PT

Financial news for THRX dated on 2013-01-28: UPDATE: Piper Jaffray Cuts PT to \$32 on Theravance Following New Convertible Offering

Financial news for THRX dated on 2013-01-28: Piper Jaffray Maintains Overweight on Theravance, Inc., Lowers PT to \$32.00

Financial news for THRX dated on 2013-01-25: Bernstein Upgrades Theravance, Inc. to Outperform

Financial news for THRX dated on 2013-01-22: Theravance Announces Exercise of Underwriter's Overallotment Option

Financial news for THRX dated on 2013-01-16: Theravance to Offer \$250 Million Convertible Subordinated Notes Due 2023

Financial news for THRX dated on 2013-01-16: Theravance to Offer \$250M Convertible Subordinated Notes Due 2023

Financial news for THRX dated on 2012-12-04: Theravance Announces Initiation of Phase 2 Study with TD-9855

Financial news for THRX dated on 2012-11-30: Wedbush Says Insmed Weakness Could Be Related to Theravance's FDA Panel Decision

Financial news for THRX dated on 2012-11-29: Theravance Shares to Resume Trading at 5:45PM EST

Financial news for THRX dated on 2012-11-29: Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

Financial news for THRX dated on 2012-11-29: FDA Panel Says Theravance's Vibativ Acceptable When No Alternatives

Financial news for THRX dated on 2012-11-29: FDA Panel Says Theravance's Vibativ

Isn't Safe or Effective in Pneumonia

Financial news for THRX dated on 2012-11-29: Theravance Halted; Pending News

Financial news for THRX dated on 2012-11-27: Theravance, GlaxoSmithKline to Advance GSK961081 to Phase 3 in 2013

Financial news for THRX dated on 2012-11-27: Theravance Offers FDA Briefing Documents for Panel Meeting on VIBATIV(R)

Financial news for THRX dated on 2012-10-30: Theravance Reports Q3 EPS \$-0.37 vs \$-0.39 Est; Revenues \$1.4M vs \$1.96M Est

Financial news for THRX dated on 2012-10-16: Theravance Will be Eligible for Payments Up to \$148M

Financial news for THRX dated on 2012-10-02: Theravance Enters Agreement With Alfa Wassermann Worth Up To \$53.5M

Financial news for THRX dated on 2012-09-12: Theravance Spikes Higher

Financial news for THRX dated on 2012-09-05: The Baupost Group's Favorite Stocks

Financial news for THRX dated on 2012-08-24: GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Financial news for THRX dated on 2012-08-16: GlaxoSmithKline Spokesperson Would Not Comment on Rumored Theravance Takeover Talks

Financial news for THRX dated on 2012-08-16: Hearing DealReporter Says Theravance Faces Wait on Possible GlaxoSmithKline Buyout

Financial news for THRX dated on 2012-07-31: Theravance Reports Q2 EPS \$-0.42 vs \$-0.44 Est; Revenues \$1.43M vs \$1.97M Est

Financial news for THRX dated on 2012-07-16: Bank of America Maintains Theravance at Buy, Raises PO from \$32 to \$34

Financial news for THRX dated on 2012-07-16: UPDATE: Stifel Nicolaus Raises PT to \$40 on Theravance on Improved Risk Profile

Financial news for THRX dated on 2012-07-16: Stifel Nicolaus Maintains Theravance at Buy, Raises PT from \$28 to \$40

Financial news for THRX dated on 2012-07-13: A Peek Into The Market Before The Trading Starts

Financial news for THRX dated on 2012-07-13: GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and Europe

Financial news for THRX dated on 2012-07-10: Dendreon, Pharmacyclics and Other Biotech Takeover Targets

Financial news for THRX dated on 2012-07-09: Theravance Spikes to New 52-Week Highs, \$28.59

Financial news for THRX dated on 2012-07-06: UPDATE: Brean Murray Carret Downgrades Theravance to Hold on Valuation

Financial news for THRX dated on 2012-07-06: Brean Murray Carret & Co. Downgrades Theravance from Buy to Hold, Removes PT

Financial news for THRX dated on 2012-07-02: Bank of America Maintains Theravance at Buy, Raises PO from \$30 to \$32

Financial news for THRX dated on 2012-07-02: Bank of America Maintains Theravance at Buy, Raises PO from \$30 to \$32

Financial news for THRX dated on 2012-07-02: GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Financial news for THRX dated on 2012-06-26: UPDATE: Option Alert: Theravance 4,691 July 17.50 Put Contracts Traded; Currently \$21.21

Financial news for THRX dated on 2012-06-26: Option Alert: Theravance Put Volume at 2,030% of Average; Currently \$21.10

Financial news for THRX dated on 2012-06-06: Morgan Stanley Reiterates Underweight

Rating, Does Not Name PT for Theravance

Financial news for THRX dated on 2012-05-16: Theravance Reports 26.7% Stake by GlaxoSmithKline

Financial news for THRX dated on 2012-04-27: Stifel Nicolaus Maintains Theravance at Buy, Raises PT from \$27 to \$28

Financial news for THRX dated on 2012-04-26: Theravance Reports Q1 EPS \$0.93 vs \$0.84 Est; Revenues \$127.1M vs \$111.83M Est

Financial news for THRX dated on 2012-04-02: Market Roundup

Financial news for THRX dated on 2012-04-02: Theravance up 22% After GlaxoSmithKline Increases Stake in Company

Financial news for THRX dated on 2012-04-02: Theravance Trading 17.8% Higher on Heavy Volume; Currently at \$22.98

Financial news for THRX dated on 2012-04-02: GlaxoSmithKline Lifts Stake In Theravance

Financial news for THRX dated on 2012-04-02: UPDATE: GlaxoSmithKline to Increase Its Ownership in Theravance

Financial news for THRX dated on 2012-03-23: GSK and Theravance Announce Completion of the Relovair(TM)* Registrational Programme and Topline Results From Relovair vs. Advair Phase III Studies in COPD

Financial news for THRX dated on 2012-03-12: UPDATE: Brean Murray Carret Initiates Coverage on Theravance

Financial news for THRX dated on 2012-03-12: Brean Murray Carret & Co. Initiates Coverage on Theravance at Buy, Announces PT of \$24

Financial news for THRX dated on 2012-02-09: Theravance Reports Q4 EPS \$(0.45) May Not Compare vs \$(0.39) Est; Revenues \$5.36M vs \$6.87M Est

Financial news for THRX dated on 2012-01-31: UPDATE: Morgan Stanley Initiates Underweight, \$12 PT on Theravance

Financial news for THRX dated on 2012-01-31: Morgan Stanley Initiates Theravance at Underweight

Financial news for THRX dated on 2012-01-11: Theravance Moving Higher on Heavy Volume

Financial news for THRX dated on 2012-01-09: Afternoon Movers; Markets Moved Higher

Financial news for THRX dated on 2012-01-09: Morning Market Losers

Financial news for THRX dated on 2012-01-09: Theravance Falls 35% on Phase III Results

Financial news for THRX dated on 2012-01-09: From Earlier: GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair in COPD and Asthma

Financial news for THRX dated on 2012-01-05: UPDATE: Piper Jaffray Raises Price Target on Theravance to \$35

Financial news for THRX dated on 2012-01-05: Piper Jaffray Raises PT on Theravance to \$35

Financial news for THRX dated on 2012-01-03: Notable Put Options Activity in Theravance

Financial news for THRX dated on 2011-12-12: Theravance Announces Initiation of Phase 2 Study With Its MARIN Compound, TD-9855, for the Treatment of ADHD

Financial news for THRX dated on 2011-12-01: Notable Put Options Activity in Theravance

Financial news for THRX dated on 2011-11-30: Notable Put Options Activity in Theravance

Financial news for THRX dated on 2011-11-14: Theravance Announces Positive Results From a Phase 2a Study of Its LAMA Candidate, TD-4208, for the Treatment of COPD

Financial news for THRX dated on 2011-10-28: UPDATE: Bank of America Raises PT to \$30

on Theravance

Financial news for THRX dated on 2011-10-28: Bank of America Raises PO on Theravance from \$26 to \$30, Maintains Buy

Financial news for THRX dated on 2011-10-19: Theravance Announces Presentation of GSK Phase 2 Data for LAMA at CHEST 2011

Financial news for THRX dated on 2011-09-27: Piper Jaffray Overweight on Theravance

Financial news for THRX dated on 2011-09-15: Astellas and Theravance Announce European Marketing Authorization for VIBATIV for Nosocomial Pneumonia Caused by MRSA

Financial news for THRX dated on 2011-07-13: Twelve Health Care ETFs Trading Near 52-Week Highs

Financial news for THRX dated on 2011-07-12: Twelve ETFs Trading Near 52-Week Highs

Financial news for THRX dated on 2011-06-28: Puts Purchased on Theravance, Inc.

Financial news for THRX dated on 2011-06-03: Benzinga's Top Downgrades

Financial news for THRX dated on 2011-06-02: GSK and Theravance Announce Results of Two Pivotal Phase III Studies for Relovair(TM) in COPD

Financial news for THRX dated on 2011-01-31: Monday's Put/Call Ratio Leaders (HRB, EXM, DF, INFN, THRX)

Financial news for THRX dated on 2011-01-31: Piper Jaffray Defends THRX Following Delayed Sell-Off

Financial news for THRX dated on 2011-01-21: CBST Beats on EPS, Misses on Sales - Analyst Blog

Financial news for THRX dated on 2011-01-21: CBST Beats on EPS, Misses on Sales - Analyst Blog

Financial news for THRX dated on 2011-01-17: Earnings Preview: Cubist Pharma - Analyst Blog

Financial news for THRX dated on 2011-01-17: Earnings Preview: Cubist Pharma - Analyst Blog

Financial news for THRX dated on 2011-01-07: Using Put/Call Ratios to Catch Bears 01-07-2011

Financial news for THRX dated on 2011-01-07: Friday's Put/Call Ratio Leaders (CHTP, CCK, GCI, THRX, GXDX)

Financial news for THRX dated on 2011-01-07: Puts Purchased on Theravance (THRX)

Financial news for THRX dated on 2010-12-29: Theravance Evenly Poised - Analyst Blog

Financial news for THRX dated on 2010-12-29: Theravance Evenly Poised - Analyst Blog

Financial news for THRX dated on 2010-12-28: Puts Purchased on Theravance (THRX)

Financial news for THRX dated on 2010-12-06: ETFs For Biotech M&A Mania

Financial news for THRX dated on 2010-11-30: Glaxo Hikes Stake in Theravance - Analyst Blog

Financial news for THRX dated on 2010-11-30: Glaxo Hikes Stake in Theravance - Analyst Blog

Financial news for THRX dated on 2010-11-29: Options Brief: Theravance, Inc. (THRX)

Financial news for THRX dated on 2010-10-25: Theravance Loss Wider Than Expected - Analyst Blog

Financial news for THRX dated on 2010-09-22: Benzinga's Volume Movers (THRX, TPCG, PRGS, ALXN)

Financial news for THRX dated on 2010-09-13: Piper Jaffray Reiterates Overweight on Theravance (THRX)

Financial news for THRX dated on 2010-09-09: COPANO EGY LLC (CPNO) - Profit Tracks

Financial news for THRX dated on 2010-09-09: Zacks Sell List Highlights: Beacon

Roofing Supply, Copano Energy, L.L.C., Jack in the Box and Theravance - Press Releases

Financial news for THRX dated on 2010-03-29: THRX Initiated With Overweight At Piper Jaffray

Financial news for THRX dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for THRX dated on 2010-01-25: My Shorting Watch-List

Financial news for THRX dated on 2009-11-30: THRX Planning Rapid Response To FDA Requests On Vibativ NP SNDA